Search clinical trials for: Monthly Ranibizumab

Total 2150 results

Novartis Pharmaceuticals

Withdrawn

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (CANARI)

Wet Age-related Macular Degeneration (Wet AMD)
Bayer

Completed

Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration (REVIEW)

Macular Degeneration

Portugal
NYU Langone Health
Agency for Healthcare Research and Quality (AHRQ)

Completed

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease

Cardiovascular Disease | High Blood Pressure

United States
Medical College of Wisconsin

Active, not recruiting

Lowering Food Insecurity and Improving Diabetes With Financial Incentives (LIFT-FINANCE)

Diabetes Mellitus, Type 2

United States
Wake Forest University Health Sciences
National Institute on Aging (NIA)

Completed

Utilizing Protein During Weight Loss to Impact Physical Function (UPLIFT)

Obesity | Weight Loss | Diet Modification | Aging | Dietary Habits | Weight Change, Body

United States
Novartis Pharmaceuticals

Completed

Rainbow Extension Study (RainbowExt)

Retinopathy of Prematurity (ROP)

United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (DRAGON)

Neovascular Age-related Macular Degeneration

China
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc.

Completed

A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (LAST)

Age Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (OCTAVE)

Neovascular Age-related Macular Degeneration

Germany, Turkey, Austria, Canada, Czechia, United Kingdom, Hungary, Italy, Lithuania, Guatemala, France, Ireland, Argentina, Portugal, Spain, Sweden, Greece, Switzerland, Slovakia, Finland, Netherlands, Colombia, Mexico, Panama
National Eye Institute (NEI)

Completed

Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Von Hippel-Lindau Syndrome

United States
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Novartis Pharmaceuticals

Completed

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment (RELIGHT)

Diabetic Retinopathy | Macular Oedema

United Kingdom
Mie University

Unknown

Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO (CRVO)

Central Retinal Vein Occlusion

Japan
Shanghai MicroPort Medical (Group) Co., Ltd.

Recruiting

Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

Coronary Disease | Percutaneous Coronary Intervention | Dual Antiplatelet Therapy | Drug Eluting Stent

China
Northwestern University
National Institute on Drug Abuse (NIDA)

Not yet recruiting

MBC2OTP Project (Measurement-Based Care Implementation in Community Opioid Treatment Programs) (MBC2OTP)

Opioid Use Disorder

United States
Subhransu K. Ray, M.D., Ph.D.
Bay Area Retina Associates

Completed

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD (Lucedex)

Exudative Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Recruiting

A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

Retinopathy of Prematurity

China
Sun Yat-sen University

Unknown

Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab (IVRDME)

Diabetic Macular Edema

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (SAFARI)

Neovascular Age-related Macular Degeneration

Germany, United Kingdom
National Eye Institute (NEI)

Completed

Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Macular Telangiectasia

United States
National Eye Institute (NEI)

Completed

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

Telangiectasia

United States
National Eye Institute (NEI)

Completed

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

Telangiectasia

United States
Novartis Pharmaceuticals

Completed

A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema (LUDIC)

Macular Edema | Visual Impairment

France
University of New Mexico
Genentech, Inc.

Completed

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Pterygium

United States
University Health Network, Toronto

Unknown

Geographic Atrophy and Intravitreal Ranibizumab Injections

Age-related Macular Degeneration | Geographic Atrophy

Canada
Bayer

Completed

Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) (AURA)

Ophthalmology, Macular Degeneration

Japan, France, Germany, Australia, Italy, United Kingdom, Venezuela, Ireland, Netherlands, Canada
Oregon Health and Science University

Completed

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

Macular Degeneration

United States
Sinocelltech Ltd.

Recruiting

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Wet Age-related Macular Degeneration

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Pathological Myopic Choroidal Neovascularization

China
University of California, San Francisco
Genentech, Inc.

Terminated

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Glaucoma

United States
Novartis Pharmaceuticals

Completed

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications (PACIFIC)

Neovascular (Wet) Age-related Macular Degeneration

Germany, Switzerland, Netherlands
Second Military Medical University

Unknown

Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery (Anti-VEGF)

Diabetic Macular Edema | Cataract

China
Johannes Gutenberg University Mainz
Novartis

Completed

Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration (CAPTAIN)

Neovascular Age-related Macular Degeneration

Germany
California Retina Consultants
Genentech, Inc.

Completed

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab (REEF)

Diabetic Macular Edema

United States
University of California, San Diego
Genentech, Inc.

Withdrawn

Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT) | Nosebleeds
University Health Network, Toronto

Completed

Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing

Age Related Macular Degeneration

Canada
University of Melbourne

Completed

Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration

Choroidal Neovascularization | Retinal Pigment Epithelial Detachment

Australia
Retina Institute of Hawaii

Completed

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD

United States
Shields, Shields and Associates

Unknown

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Uveal Melanoma | Radiation Retinopathy | Radiation Maculopathy

United States
London School of Hygiene and Tropical Medicine
Radboud University Medical Center; Centre national de recherche et de formation... and other collaborators

Completed

P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)

Malaria

Burkina Faso
Western Health, Australia

Completed

Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease (EMAN-Anaemia)

Anemia | Kidney Failure, Chronic

Australia
Pontificia Universidad Catolica de Chile
University Diego Portales

Not yet recruiting

Effectiveness of a Short and Telematic Version of Cognitive-behavioral Treatment for Borderline Personality Disorder

Borderline Personality Disorder

Chile
Hospices Civils de Lyon

Completed

Gastric Volumetry by Gastric Tomodensitometry With Gas (VOLUSCAN)

Morbid Obesity

France
University Hospital, Strasbourg, France

Unknown

Evaluation of the Efficacy of Optometric Rehabilitation on Visual Cognitive Deficits in Children

Visual Cognitive Deficits

France
Novartis Pharmaceuticals

Recruiting

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Korea, Republic of
University of California, San Diego
Genentech, Inc.

Completed

Study EvAluating Genotypes While Using Lucentis 2 (SEAGUL2)

Age-Related Macular Degeneration

United States
Retina Vitreous Associates of Florida
Genentech, Inc.

Completed

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

Diabetic Retinopathy | Macular Edema

United States
Moorfields Eye Hospital NHS Foundation Trust
Novartis

Completed

The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema

Uveitis Related Cystoid Macular Edema | Steroid-induced Glaucoma - Borderline

United Kingdom
Novartis Pharmaceuticals

Completed

A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. (OLIMPIC)

Choroidal Neovascularization Secondary to Pathologic Myopia

Italy
Kagawa University
Novartis Pharmaceuticals

Completed

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

Diabetic Macular Edema

Japan

Search clinical trials for: Monthly Ranibizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations